Select a Region North America

Insights

Insights From Our Experts

Articles

‘Pharmatizing’ AI in Pharma

Amazon Web Services and EVERSANA are partners at the epicenter of transforming life sciences commercialization through technology solutions including AI. Experts Scott Snyder, Chief Digital Officer, EVERSANA, and Dr. Shakthi Kumar, Worldwide Head, Healthcare and Life…

Driving Patient-First Affordability in Seconds – Not Days: Accelerating Time to Therapy

Fewer than 60% of Pharmacy Benefit Manager (PBM) electronic benefit verifications (eBVs) accurately assess patients’ financial responsibilities, largely due to the industry’s reliance on AI algorithms for estimations. This leads to financial barriers for patients, hesitancy…

Adapting to Change: Examining the Implications of New EU Regulations on Commercialisation from the Perspectives of Patients, Providers, and Pharma Companies

In April, the European Federation of Pharmaceutical Industries and Associations’ (EFPIA) 2022 Patient W.A.I.T Indicator found that the average rate of availability for pharmaceuticals in Europe is 45%, down 2% on the previous year. Additionally, the…

Making Primary Market Research SMARTER Through Social Listening

Discover how EVERSANA is transforming the landscape of primary market research in the pharmaceutical industry through our unique approach to social listening. This insightful article from our APAC team highlights the common challenges faced by pharma…

Utilization of Indirect Treatment Comparison (ITC), External Control Arms (ECA) and Patient-Reported Outcome Measures (PROMs)

Health Technology Assessment (HTA) is crucial to assessing the effectiveness, safety and cost-effectiveness of healthcare interventions. Indirect Treatment Comparison (ITC) is one trend that has gained traction in the HTA space as a way to evaluate…

Lead Time Is All You Need: Patient Identification for Cell and Gene Therapies Using Machine Learning and Advanced Data Analytics

Discover how EVERSANA’s cutting-edge approach is revolutionizing patient identification for cell and gene therapies. In our white paper, “Lead Time Is All You Need: Patient Identification for Cell and Gene Therapies Using Machine Learning and Advanced…

Delivering Value to Leading Payers
Delivering Value to Leading Payers

Assessment of Strategic Priorities, Competitive Dynamics, and Innovations Impacting Biopharma Access Seven leading payers represent nearly half of all US medical lives and 54% of pharmacy lives: UnitedHealth Group CVS Health, Cigna Elevance Health Kaiser Permanente…

APACMed Digital Health Reimbursement Policy Forum

Introduction The APACMed Policy Forum on Digital Health Reimbursement was held on 23 May 2023, with participants from Australia, Japan, Singapore, South Korea, Germany, France, and the UK. Several digital health policymakers, academicians, and experts from…

Considerations for Globalization of Medical Information Services: A Service Partner Perspective

This poster details the considerations for globalizing medical information (MI) services. Traditionally, pharmaceutical companies began in one geographical region before expanding, but evolving regulations and research priorities for rare diseases, oncology/hematology, immunology, and cell and gene…

New Models of Benefits Verification Solve for Complexity, Accelerate Speed to Therapy and Deliver Price Transparency

Navigating health care insurance coverage can be a supremely convoluted process for anyone, especially patients or caregivers recently faced with coping with a life-threatening disease. While the advancement of many new treatments and scientific innovations in…